KemPharm Inc. (KMPH) Sees Strong Trading Volume
Shares of KemPharm Inc. (NASDAQ:KMPH) saw unusually-high trading volume on Friday . Approximately 123,918 shares were traded during trading, an increase of 91% from the previous session’s volume of 65,007 shares.The stock last traded at $4.18 and had previously closed at $4.03.
KMPH has been the subject of several analyst reports. Canaccord Genuity restated a “buy” rating on shares of KemPharm in a report on Tuesday, May 3rd. Zacks Investment Research downgraded KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 4th. Royal Bank Of Canada reduced their price target on KemPharm from $22.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, May 6th. Finally, Oppenheimer Holdings Inc. restated a “buy” rating on shares of KemPharm in a report on Saturday, May 14th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $26.80.
The firm’s market capitalization is $61.79 million. The company has a 50 day moving average of $4.32 and a 200-day moving average of $11.27.
KemPharm (NASDAQ:KMPH) last announced its quarterly earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.26. Analysts predict that KemPharm Inc. will post ($2.79) earnings per share for the current fiscal year.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.